Abstract:Combination therapy via stimulus-responsive drug release is known to improve treatment efficacy and minimize side effects. However, the use of low-abundance cancer biomarkers as molecular triggers to induce efficient drug release for combination therapy still remains a challenge. Herein, we developed a dual microRNA-responsive drug nanocarrier for catalytic release of doxorubicin (Dox) and small interfering RNA (siRNA) in cancerous cells for combined chemotherapy and gene therapy with logic operation. The nanocarrier is constructed by assembling two duplexes of DNA/RNA and Dox molecules onto DNA-functionalized gold nanoparticles. Two microRNA molecules (miRNA-21 and miRNA-10b overexpressed in MDA-MB-231) could alternatively catalyze the disassembly of the nanocarrier through a thermodynamically driven entropy gain process, during which Dox molecules are released, and the two pairs of released DNA/RNA duplex hybridize to generate siRNA (siBcl-2) in situ by strand displacement reactions. Quantum dots are used to track the process in living cells. The AND logic gate-based drug release system allows effective treatment of specific cancer cell types according to miRNA expression patterns. This strategy represents an effective means to overcome multidrug resistance and improve therapeutic effects.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c09494?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c09494</a>.Materials and methods including characterization of GNPs (Figure S1), characterization of DNA2-QD (Figure S2), characterization of DNA hybridization (Figure S3), PAGE analysis of the strand displacement reaction (Figure S4), FL and ICP data for determination of the D1D′1C and D2DQ number (Figure S5), characterization of catalytic disassembly of Dox-GNC (Figure S6), stability test of Dox-GNC (Figure S7), agarose gel electrophoresis characterization of disassembly of GNC (Figure S8), determination of Dox loading on GNC (Figure S9), specificity of Dox-GNC triggered by dual miRNAs for drug release (Figure S10), stability of GNC at physiological circumstances (Figure S11), cell viabilities of three cell lines treated with GRR-Dox in the presence or absence of fuel DNA for different times (Figure S12), cell viabilities of MDA-MB-231 cells transfected with waste DNA (Figure S13), cell viabilities of MDA-MB-231 cells under different treatments (Figure S14), and expression level of the Bcl-2 protein measured with western blot (Figure S15) (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c09494/suppl_file/am0c09494_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Nanocarriers with Multi-Locked DNA Valves Targeting Intracellular Tumor-Related Mrnas for Controlled Drug Release

Polymeric Nanostructure Compiled with Multifunctional Components to Exert Tumor-Targeted Delivery of Antiangiogenic Gene for Tumor Growth Suppression

Dual-Targeted Nanocarrier Based on Cell Surface Receptor and Intracellular Mrna: an Effective Strategy for Cancer Cell Imaging and Therapy

Dna-Hybrid-Gated Multifunctional Mesoporous Silica Nanocarriers for Dual-Targeted and Microrna-Responsive Controlled Drug Delivery**

Near Infrared-Guided Smart Nanocarriers for MicroRNA-Controlled Release of Doxorubicin/siRNA with Intracellular ATP As Fuel.

Terminal Deoxynucleotidyl Transferase-Catalyzed Preparation of Ph-Responsive DNA Nanocarriers for Tumor-Targeted Drug Delivery and Therapy.

Hierarchical Nanocarriers for Precisely Regulating the Therapeutic Process via Dual-Mode Controlled Drug Release in Target Tumor Cells

Hierarchical Integration of Degradable Mesoporous Silica Nanoreservoirs and Supramolecular Dendrimer Complex As a General-Purpose Tumor-Targeted Biomimetic Nanoplatform for Gene/small-Molecule Anticancer Drug Co-Delivery

A Smart Nanoassembly for Multistage Targeted Drug Delivery and Magnetic Resonance Imaging

A Drug-Self-gated and Tumor Microenvironment-Responsive Mesoporous Silica Vehicle: "Four-in-one" Versatile Nanomedicine for Targeted Multidrug-Resistant Cancer Therapy

Lanthanide-integrated supramolecular polymeric nanoassembly with multiple regulation characteristics for multidrug-resistant cancer therapy

A Near‐Infrared Light‐Triggered Nanocarrier with Reversible DNA Valves for Intracellular Controlled Release

Dual MicroRNA-Triggered Drug Release System for Combined Chemotherapy and Gene Therapy with Logic Operation

mRNA-responsive two-in-one nanodrug for enhanced anti-tumor chemo-gene therapy

Nanocarrier Based on the Assembly of Protein and Antisense Oligonucleotide to Combat Multidrug Resistance in Tumor Cells

A Tumor Mrna-Dependent Gold Nanoparticle-Molecular Beacon Carrier for Controlled Drug Release and Intracellular Imaging.

In Vivo Dual-Targeted Chemotherapy of Drug Resistant Cancer by Rationally Designed Nanocarrier.

Rationally designed DNA-based nanocarriers

CRISPR-dCas9-Guided and Telomerase-Responsive Nanosystem for Precise Anti-Cancer Drug Delivery.

Programmable Metal/Semiconductor Nanostructures for mRNA-Modulated Molecular Delivery.

Inhibition of Multidrug Resistance of Cancer Cells by Co‐Delivery of DNA Nanostructures and Drugs Using Porous Silicon Nanoparticles@Giant Liposomes